Viral Nonstructural Proteins
"Viral Nonstructural Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins encoded by a VIRAL GENOME that are produced in the organisms they infect, but not packaged into the VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY.
| Descriptor ID |
D017361
|
| MeSH Number(s) |
D12.776.964.900
|
| Concept/Terms |
Viral Nonstructural Proteins- Viral Nonstructural Proteins
- Proteins, Viral Nonstructural
- NS Proteins, Viral
- Proteins, Viral NS
- Viral Nonstructural Protein
- Nonstructural Protein, Viral
- Protein, Viral Nonstructural
- Viral NS Proteins
- Nonstructural Proteins, Viral
- Viral Non-Structural Proteins
- Non-Structural Proteins, Viral
- Proteins, Viral Non-Structural
- Viral Non Structural Proteins
|
Below are MeSH descriptors whose meaning is more general than "Viral Nonstructural Proteins".
Below are MeSH descriptors whose meaning is more specific than "Viral Nonstructural Proteins".
This graph shows the total number of publications written about "Viral Nonstructural Proteins" by people in this website by year, and whether "Viral Nonstructural Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Nonstructural Proteins" by people in Profiles.
-
Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 a-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. J Mol Graph Model. 2020 12; 101:107730.
-
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
-
Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017 08; 17(8):843-853.
-
Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa. Antiviral Res. 2016 Mar; 127:90-8.
-
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17; 370(16):1483-93.
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16; 370(3):211-21.
-
Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
-
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis. 2006 Feb 15; 193(4):573-81.
-
Hepatitis B virus X protein does not influence essential steps of nucleotide excision repair effected by human liver extracts. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):806-10.